Aster DM Healthcare Ltd

Aster DM Quality Care Ltd has announced that its Board of Directors will convene on August 5, 2026. The primary agenda item for this meeting is to consider and approve the unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026. This announcement is made in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Aster DM Healthcare Limited (now Aster DM Quality Care Limited) has reported a significant change in its promoter and promoter group shareholding. Following the allotment of equity shares on July 13, 2026, as part of the Scheme of Amalgamation with Quality Care India Limited (QCIL), the aggregate shareholding of Aster Promoters has decreased from 40.39% to 24.01%. This dilution is a result of equity shares being allotted to eligible QCIL shareholders at a ratio of 977 shares of Aster DM for every 1,000 QCIL shares. The disclosure is made under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, indicating a dilution of over 2% in the promoter's stake.

BCP Asia II Topco IV Pte. Ltd., along with Persons Acting in Concert (PACs), has disclosed a substantial acquisition of shares in Aster DM Quality Care Limited (formerly Aster DM Healthcare Limited). The acquisition, which occurred pursuant to a Scheme of Amalgamation sanctioned by the NCLT, involved the allotment of 24,49,96,597 equity shares, representing 28.11% of the total share capital. This transaction increases the acquirer's total holding, including PACs, to 25,89,52,574 shares, or 29.71% of the total voting capital. The acquisition was completed on July 13, 2026, with the shares being allotted based on a specified share exchange ratio.

Aster DM Healthcare Limited has approved the allotment of 35,35,51,410 fully paid-up equity shares of face value INR 10/- each to the eligible shareholders of the erstwhile Transferor Company, Quality Care India Limited (QCIL), as per the approved Scheme of Amalgamation. This allotment is based on a share exchange ratio of 977 Transferee Company shares for every 1,000 Transferor Company shares. The transaction follows the NCLT's approval of the scheme on June 19, 2026. Consequently, Aster DM Healthcare's issued, subscribed, and paid-up equity share capital has increased from INR 5,18,12,10,290 to INR 8,71,67,24,390. The newly allotted shares will rank pari passu with existing shares and will be listed on BSE and NSE.

BCP Asia II Topco IV Pte Ltd has filed a disclosure with the stock exchanges seeking exemption from making an open offer under Regulation 10(1)(d)(ii) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. This follows a Scheme of Amalgamation between Quality Care India Limited and Aster DM Healthcare Limited, sanctioned by the NCLT. Post-amalgamation, BCP will become a promoter of Aster Quality Care and will be allotted 24,49,96,597 equity shares. The filing indicates BCP will hold 29.71% of the diluted share capital post-allotment. The record date for determining shareholder entitlement is July 9, 2026.

Aster DM Healthcare Limited has officially changed its name to Aster DM Quality Care Limited, effective July 3, 2026. This change follows the receipt of a fresh Certificate of Incorporation pursuant to change of name from the Registrar of Companies (RoC-Telangana). The company was originally incorporated as DM Healthcare Private Limited. The name change does not affect the rights and liabilities of stakeholders. The company is obligated to display its old name alongside the new name for two years.

Aster DM Healthcare Ltd announced updated outcomes from its Board of Directors meeting held on July 1, 2026. The board approved several director appointments, including Mr. Varun Khanna as Managing Director & Group CEO, and Mr. Neeraj Jain, Mr. Kewal Handa, and Mr. V K Mathews as Independent Directors. It also noted the resignation of several directors and changes in Senior Management Personnel (SMP) due to organizational restructuring and a resignation. The company is responding to BSE's request for additional details regarding listed entities where resigning directors hold directorships.

Aster DM Healthcare Ltd has announced the successful completion of its merger with Quality Care India Limited (QCIL). The combined entity, now operating as Aster Quality Care, brings together four healthcare brands: Aster DM, CARE Hospitals, Evercare, and KIMSHEALTH. The merged company will operate 39 hospitals across 28 cities with over 10,600 beds, focusing on expanding advanced healthcare services beyond metropolitan areas into tier 2 and tier 3 cities. Dr. Azad Moopen will serve as Executive Chairman, and Mr. Varun Khanna as Managing Director and Group CEO. The merger aims to create a stronger platform for accessible, advanced healthcare, leveraging synergies in clinical collaboration, technology, and operations.

Aster DM Healthcare Ltd has updated the contact details for its Key Managerial Personnel (KMP) authorized to determine the materiality of events and make disclosures to stock exchanges, as per SEBI regulations. The updated list includes Mr. Varun Khanna (Managing Director and Group CEO), Mr. Sunil Kumar M R (Group Chief Financial Officer), and Mr. Hemish Purushottam (Company Secretary & Compliance Officer), along with their respective email addresses. This intimation is also available on the company's website.

Aster DM Healthcare Ltd has announced significant changes in its senior management and board of directors, effective July 1, 2026. These changes are part of the implementation of a Scheme of Amalgamation and consequent organizational restructuring. Key appointments include Mr. Varun Khanna as Managing Director & Group Chief Executive Officer and several new Independent and Non-Executive Directors. The company also noted the resignation of two Independent Directors and two Non-Executive Directors. Additionally, Mr. Hitesh Dhaddha will resign as Chief Investor Relations and M&A Officer on July 18, 2026. The filing also details changes in committee compositions and a revised list of Senior Management Personnel (SMPs) including new Chief Executive Officers for various regions and new group-level officers.